Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPRX002
- Development stage
- Phase 1
- Lead developer
- Arcellx
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
SPRX002 is a monovalent, soluble protein that acts as a CD123-specific adapter molecule. It is used in combination with universal antigen receptor complex T cells (ARC-T cells) as part of the ARC-SparX platform for the treatment of relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). SPRX002 binds to CD123-expressing tumor cells and serves as a bridge between these target cells and ARC-T cells, which recognize SPRX002 through an anti-tag domain. This enables targeted cytotoxicity against CD123+ cancer cells. The dose of SPRX002 can be adjusted to modulate the activity and safety profile of ARC-T cell therapy, potentially reducing toxicity. The drug is currently being evaluated in phase 1 clinical trials for AML and high-risk MDS[1][2][3][4][5][7].
- Other names
- cd123-specific adapter sprx002cd-123-specific adapter sprx002cd 123-specific adapter sprx002
02
Targets
IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on SPRX002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPRX002.